

Analysis of variance for Ln-transformed pharmacokinetic parameters revealed as follows:

C_{max} formulation sequence and period effect for Ln-transformed pharmacokinetic parameters were statistically insignificant at 5% level of significance.

AUC_{0-t} period effect for Ln-transformed pharmacokinetic parameters was statistically significant where as formulation and sequence effect is statistically insignificant at 5% level of significance.

$AUC_{0-\infty}$ formulation period and sequence effect for Ln-transformed pharmacokinetic parameters were statistically insignificant.

Based on the results obtained in this study, it can be concluded that Anastrozole tablets 1 mg (Test) and Arimidex[®] (containing Anastrozole) tablets 1 mg (Reference) are bioequivalent in 12 healthy, adult, postmenopausal/surgically sterile female human subjects under fasting conditions.

ACKNOWLEDGEMENT:

The authors wish to express their hearty gratitude to Micro Therapeutics Research Labs Pvt. Ltd for overall support.

REFERENCE

1. Indian Council of Medical Research (ICMR): Ethical guidelines for medical research on human Subjects 2006.
2. "Good Clinical Practices for clinical research in India" guidelines – Schedule Y (Amended version 2005).
3. International Conference on Harmonization (ICH): Harmonized Tripartite Guideline – Guideline for Good Clinical Practice (GCP) – E6, 1996.
4. 21 CFR (Code of Federal Regulations): Section 50 and 56
Section 50: Protection of Human Subjects
Section 56: Institutional Review Boards
5. "Guideline for Industry – Structure and content of Clinical Study Report", ICH – E3, CDER Guidance Documents / FDA July 1996
6. Declaration of Helsinki (Seoul 2008).
7. SAS/STAT volume II, 4th edition, Chapter 32, SAS Institute Inc., USA Release 9.1.3.
8. Code of Federal Regulations (CFR), Title 21, section 320.38 - Retention of bioavailability samples.
9. Prescribing Information:
 - <http://www1.astrazeneca-us.com/pi/arimidex.pdf>
 - http://www.theodora.com/drugs/arimidex_tablets_astrazeneca.html
 - http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020541s020s021s023lbl.pdf